AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect

AbbVie (NYSE:ABBV) disappointed investors the last time when it reported its 2018 fourth-quarter in January. The big drugmaker missed Wall Street analysts' estimates on both the top and bottom lines.

The culprit? Worse than expected sales for Humira in the wake of biosimilar competition in Europe. AbbVie's share price has floundered so far this year in large part because of concerns about Humira, with the stock down 15% year to date.